474 related articles for article (PubMed ID: 29143315)
1. Fetal haemoglobin induction in sickle cell disease.
Paikari A; Sheehan VA
Br J Haematol; 2018 Jan; 180(2):189-200. PubMed ID: 29143315
[TBL] [Abstract][Full Text] [Related]
2. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.
Lettre G; Sankaran VG; Bezerra MA; Araújo AS; Uda M; Sanna S; Cao A; Schlessinger D; Costa FF; Hirschhorn JN; Orkin SH
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11869-74. PubMed ID: 18667698
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
Lohani N; Bhargava N; Munshi A; Ramalingam S
J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
[TBL] [Abstract][Full Text] [Related]
4. Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells.
Zhang Y; Paikari A; Sumazin P; Ginter Summarell CC; Crosby JR; Boerwinkle E; Weiss MJ; Sheehan VA
Blood; 2018 Jul; 132(3):321-333. PubMed ID: 29884740
[TBL] [Abstract][Full Text] [Related]
5. Original Research: A case-control genome-wide association study identifies genetic modifiers of fetal hemoglobin in sickle cell disease.
Liu L; Pertsemlidis A; Ding LH; Story MD; Steinberg MH; Sebastiani P; Hoppe C; Ballas SK; Pace BS
Exp Biol Med (Maywood); 2016 Apr; 241(7):706-18. PubMed ID: 27022141
[TBL] [Abstract][Full Text] [Related]
6. Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease.
Menzel S; Thein SL
Mol Diagn Ther; 2019 Apr; 23(2):235-244. PubMed ID: 30478714
[TBL] [Abstract][Full Text] [Related]
7. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.
Flanagan JM; Steward S; Howard TA; Mortier NA; Kimble AC; Aygun B; Hankins JS; Neale GA; Ware RE
Br J Haematol; 2012 Apr; 157(2):240-8. PubMed ID: 22360576
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
9. MIR-144-mediated NRF2 gene silencing inhibits fetal hemoglobin expression in sickle cell disease.
Li B; Zhu X; Ward CM; Starlard-Davenport A; Takezaki M; Berry A; Ward A; Wilder C; Neunert C; Kutlar A; Pace BS
Exp Hematol; 2019 Feb; 70():85-96.e5. PubMed ID: 30412705
[TBL] [Abstract][Full Text] [Related]
10. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children.
Estepp JH; Smeltzer MP; Wang WC; Hoehn ME; Hankins JS; Aygun B
Br J Haematol; 2013 May; 161(3):402-5. PubMed ID: 23384083
[TBL] [Abstract][Full Text] [Related]
11. Post-Transcriptional Genetic Silencing of
Esrick EB; Lehmann LE; Biffi A; Achebe M; Brendel C; Ciuculescu MF; Daley H; MacKinnon B; Morris E; Federico A; Abriss D; Boardman K; Khelladi R; Shaw K; Negre H; Negre O; Nikiforow S; Ritz J; Pai SY; London WB; Dansereau C; Heeney MM; Armant M; Manis JP; Williams DA
N Engl J Med; 2021 Jan; 384(3):205-215. PubMed ID: 33283990
[TBL] [Abstract][Full Text] [Related]
12. Haemoglobin F modulation in childhood sickle cell disease.
Trompeter S; Roberts I
Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119
[TBL] [Abstract][Full Text] [Related]
13. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
Rivers A; Vaitkus K; Jagadeeswaran R; Ruiz MA; Ibanez V; Ciceri F; Cavalcanti F; Molokie RE; Saunthararajah Y; Engel JD; DeSimone J; Lavelle D
Exp Hematol; 2018 Nov; 67():60-64.e2. PubMed ID: 30125603
[TBL] [Abstract][Full Text] [Related]
15. Identifying genetic variants and pathways associated with extreme levels of fetal hemoglobin in sickle cell disease in Tanzania.
Nkya S; Mwita L; Mgaya J; Kumburu H; van Zwetselaar M; Menzel S; Mazandu GK; Sangeda R; Chimusa E; Makani J
BMC Med Genet; 2020 Jun; 21(1):125. PubMed ID: 32503527
[TBL] [Abstract][Full Text] [Related]
16. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
Mahmoud Ahmed NH; Lai MI
Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
Saunthararajah Y; DeSimone J
Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic reactivation of fetal haemoglobin.
Olivieri NF; Weatherall DJ
Hum Mol Genet; 1998; 7(10):1655-8. PubMed ID: 9735388
[TBL] [Abstract][Full Text] [Related]
19. Functional polymorphisms of BCL11A and HBS1L-MYB genes affect both fetal hemoglobin level and clinical outcomes in a cohort of children with sickle cell anemia.
Sales RR; Belisário AR; Faria G; Mendes F; Luizon MR; Viana MB
Ann Hematol; 2020 Jul; 99(7):1453-1463. PubMed ID: 32447424
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
Cui S; Engel JD
Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
